Geron Corporation
Tracked across 4 events · 41 articles · First seen Mar 13, 2025 · Last active May 25, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: Geron Corporation is the defendant in multiple class action lawsuits alleging securities fraud due to misleading statements about the launch and growth potential of its drug Rytello, which led to a significant stock price decline.
Mar 13, 2025 · 23 articles
Regulatory
Impact: Geron Corporation is facing a federal securities class action lawsuit due to alleged false and misleading statements regarding its drug Rytelo, which led to a significant stock price decline.
Mar 14, 2025 · 6 articles
Regulatory
Impact: Geron Corporation is facing multiple securities class action lawsuits for allegedly making false and misleading statements regarding the launch success and potential growth of its product, RYTELO, which could negatively impact its stock price and reputation.
Mar 25, 2025 · 6 articles
Tech
Geron Corporation announced that the first real-world evidence study of its drug RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) will be presented at the European Hematology Association (EHA) 2026 Congress. The investigator-sponsored study,…
Impact: Geron Corporation announced positive real-world evidence study results for its drug RYTELO (imetelstat) in lower-risk myelodysplastic syndromes (LR-MDS), which supports its continued use and potential for expanded treatment options.
May 12, 2026 · 6 articles
100
Geron Corporation announced study resultsGeron RYTELO LR-MDS Study Results
50
Geron Corporation will presentGeron RYTELO LR-MDS Study Results
NEWSDESK
Track Geron Corporation live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard